论文部分内容阅读
Background:The EFFORT study have concluded that adjusting treatment strategy is recommended for suboptimal virological responders to telbivudine(LdT) at week 24,adding on adefovir(ADV) can benefit these patients with additive antiviral potency for HBeAg positive chronic hepatitis B(CHB) patients.